Compare Gilead Sciences, Inc. (GILD) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Snap On Incorporated — how do they compare? Gilead Sciences, Inc. trades at $132.94 (market cap $163.51B), while Snap On Incorporated trades at $412.52 (market cap $20.91B). The key difference: Gilead Sciences, Inc. is far larger — about 7.8× Snap On Incorporated's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | SNA | |
|---|---|---|
Market Cap | $163.51B | $20.91B |
Sector | Health | Technology |
52-Week High | $155.80 | $413.62 |
52-Week Low | $108.22 | $313.01 |
Enterprise Value | $178.05B | $20.43B |
Dividend Yield | 2.49% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SNA trades at $411.07, up 1.59% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $407.50. Recent Q1 2026 earnings missed estimates, but revenue grew 5.8% year-over-year, and the company maintains strong profitability with a 19.6% net income margin. Strategic acquisitions like Diesel Laptops for $100 million (Business Wire, June 9, 2026) aim to expand heavy-duty diagnostics capabilities.
The stock offers steady dividend income and share repurchases but faces risks from muted growth projections and margin pressures. Analyst sentiment is predominantly bullish (64.7% buy ratings), though valuation at a P/E of 20.84 may limit upside if earnings growth disappoints. Key catalysts include Q2 2026 results on July 23, 2026, with investors watching for organic sales momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
